The EPO published patent EP3997123A1 for a refining method of ophthalmic protein pharmaceuticals developed by Sam Chun Dang Pharm. CO., LTD. The patent covers IPC classifications including C07K 16/22 (anti-VEGF antibodies), C07K 1/18 (protein purification methods), and A61P 27/02 (ophthalmic therapeutics). The application is designated across 44 European contracting states including all major EU markets.

Pharmaceutical and biotechnology companies developing ophthalmic protein-based therapeutics should assess whether this patented refining method overlaps with their manufacturing processes or product pipelines. Competitors may need to explore alternative purification techniques or consider licensing arrangements. No immediate compliance actions are required from this publication notice, though IP teams should update patent landscape analyses for ophthalmic protein development programs.